content: <html>
  
  <head>
  
  
  
  
  
  </head>
  
  <body lang="EN-US" style="text-justify-trim: punctuation">
  
  <div style="font-family:Times New Roman;">
  
  <div style="border:none;border-top:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
  STATES<br>
  SECURITIES AND EXCHANGE COMMISSION<br>
  </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
  REPORT<br>
  Pursuant to Section&nbsp;13 OR 15(d)&nbsp;of The Securities Exchange Act of
  1934</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report
  (Date of earliest event reported):&nbsp; <b>April&nbsp;30, 2008</b></font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Sepracor
  Inc.</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of
  Registrant as Specified in its Charter)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-19410</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">22-2536587</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other
    Juris-<br>
    diction of Incorporation</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission<br>
    File Number)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer<br>
    Identification No.)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">84
    Waterford Drive<br>
    Marlborough, MA</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><br>
    01752</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal
    Executive Offices)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
  telephone number, including area code:&nbsp; <b>(508)
  481-6700</b></font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or
  Former Address, if Changed Since Last Report)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions (see General Instruction A.2. below):</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425
  under the Securities Act (17 CFR 230.425)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12
  under the Exchange Act (17 CFR 240.14a-12)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant
  to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant
  to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tbamidi\08-13159-2\task2907807\13159-2-ba.htm',USER='tbamidi',CD='Apr 30 19:30 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01&#160; Entry into a Material Definitive Agreement.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Levalbuterol/ipratropium License
  and Development Agreement</font></i></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;30, 2008,
  Sepracor Inc. (the &#147;Company&#148;) entered into a License and Development Agreement
  (the &#147;Levalbuterol/ipratropium Agreement&#148;) with Arrow International Limited
  (&#147;Arrow&#148;) for the development, commercialization, marketing, sale and
  distribution of Arrow&#146;s levalbuterol/ipratropium combination inhalation
  solution product in current and all future formulations and delivery modes (the
  &#147;Levalbuterol/ipratropium Product&#148;) throughout the world.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the
  Levalbuterol/ipratropium Agreement, Arrow will receive an upfront payment of
  $500,000 upon execution of the Levalbuterol/ipratropium Agreement.&#160; Arrow shall also be entitled to receive a
  $25,000,000 payment on December&nbsp;15, 2009, a $25,000,000 payment on December&nbsp;15,
  2010 as further consideration for the transfer of know how and the grants of
  rights and licenses to the Arrow technology, provided Arrow is not in material
  breach of certain of its obligations under the Levalbuterol/ipratropium
  Agreement, and a milestone payment of $20,000,000 upon receipt of marketing
  clearance for the Levalbuterol/ipratropium Product in the United States. The
  Company will also pay single-digit royalties that escalate based on product
  sales, subject to Arrow electing to receive a discounted amount in lieu of
  ongoing royalty payments.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will have
  responsibility for all aspects of the development and commercialization of the
  Levalbuterol/ipratropium Product.&#160; The
  Company will fully fund all product development activities and manage the
  development program, including all interactions with the U.S. Food and Drug
  Administration and other regulatory bodies.&#160;
  Arrow will assist the Company with the development.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Arrow has the right to
  manufacture and supply the Company with its requirements of the
  Levalbuterol/ipratropium Product.&#160; If
  Arrow elects not to manufacture and supply the Levalbuterol/ipratropium Product
  to the Company, then the Company will have the right to manufacture or arrange
  for the manufacture of the Levalbuterol/ipratropium Product.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
  Levalbuterol/ipratropium Agreement will remain in effect until the later of, on
  a product by product basis, the last to expire of any patent with a claim
  covering the Levalbuterol/ipratropium Product, or 12 years after the first
  commercial sale of the Levalbuterol/ipratropium Product on a country by country
  basis.&#160; The agreement also contains
  customary early termination and non-compete provisions.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Ciclesonide License and
  Development Agreement</font></i></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;30,
  2008, the Company entered into a License and Development Agreement (the
  &#147;Ciclesonide Agreement&#148;) with Arrow for the development, commercialization,
  marketing, sale and distribution of an inhalation pharmaceutical product
  containing ciclesonide as its only active ingredient and an inhalation
  pharmaceutical product containing both ciclesonide and arformoterol as its
  active ingredients throughout the world (collectively, the &#147;Ciclesonide Products&#148;)
  as well as Arrow&#146;s &#147;U-Bend&#148; packaging technology which allows increased
  accuracy in dosing through a novel U-Bend ampule design.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the
  Ciclesonide Agreement, Arrow will receive an upfront payment of $500,000 upon
  execution of the Ciclesonide Agreement.&#160;
  Arrow shall also be entitled to receive a $10,000,000 payment on December&nbsp;15,
  2009, a $10,000,000 payment on December&nbsp;15, 2010, as further consideration
  for the transfer of know how and the grants of rights and licenses to the Arrow
  technology, provided Arrow is not in material breach of certain of its
  obligations under the Levalbuterol/ipratropium Agreement, and milestone
  payments of up to an aggregate of $27,500,000 upon the achievement of certain
  regulatory milestones relating to both the Ciclesonside Products.&#160; The Company will also pay single-digit
  royalties on sales of the Ciclesonide Products, subject to Arrow electing to
  receive discounted amounts in lieu of ongoing royalty payments.</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\tbamidi\08-13159-2\task2907807\13159-2-ba.htm',USER='tbamidi',CD='Apr 30 19:30 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company and
  Arrow will be jointly responsible for the development of the Ciclesonide
  Products.&#160; The Company will fully fund
  all product development activities and manage the development program,
  including all interactions with the U.S. Food and Drug Administration and other
  regulatory bodies.&#160; The Company is
  exclusively responsible for all commercial activities associated with the
  Ciclesonide Products.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Ciclesonide
  Agreement will remain in effect until the later of, on a product by product
  basis, the last to expire of any patent with a claim covering the Ciclesonide
  Products, or 12 years after the first commercial sale of one of the Ciclesonide
  Products on a country by country basis.&#160;
  The Ciclesonide Agreement also contains customary early termination and
  non-compete provisions.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Forward-Looking Statements</font></i></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Report on Form&nbsp;8-K
  contains forward-looking statements that involve risks and uncertainties,
  including statements with respect to the development, commercialization,
  marketing, sale, and distribution of products containing
  levalbuterol/ipratropium, ciclesonide, and ciclesonide/arformoterol, the supply
  of finished product by Arrow and future payments by the Company to Arrow.&#160; Among the factors that could cause actual
  results to differ materially from those indicated by such forward-looking
  statements are: the clinical benefits, efficacy and safety of products covered
  by the agreements referenced in this report; the timing and success of the
  development of products covered by the agreements referenced in this report;
  unexpected delays in commercial introduction and the commercial success of
  products covered by the agreements referenced in this report; Arrow&#146;s ability
  to supply or obtain from third parties the Company&#146;s requirements for products
  or components covered by the Agreement; the success of the Company&#146;s
  relationship with Arrow; the scope of Arrow&#146;s and/or the Company&#146;s patents and
  the patents of others; the ability of the Company and Arrow to attract and
  retain qualified personnel; and certain other factors that may affect future
  operating results that are detailed in the Company&#146;s annual report on Form&nbsp;10-K
  for the year ended December&nbsp;31, 2007 filed with the Securities and
  Exchange Commission.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the
  statements in this Report on Form&nbsp;8-K represent the Company&#146;s expectations
  and beliefs as of the date of this Report. Subsequent events and developments
  may cause these expectations and beliefs to change. However, while the Company
  may elect to update these forward-looking statements at some point in the
  future, unless required by applicable law, it specifically disclaims any
  obligation to do so.&#160; These
  forward-looking statements should not be relied upon as representing the
  Company&#146;s expectations or beliefs as of any date subsequent to the date of this
  Report on Form&nbsp;8-K.</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\tbamidi\08-13159-2\task2907807\13159-2-ba.htm',USER='tbamidi',CD='Apr 30 19:30 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURES</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="52%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sepracor Inc.</font></p>
    </td>
   </tr>
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="45%" valign="top" style="padding:0in .7pt 0in .7pt;width:45.58%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;1, 2008</font></p>
    </td>
    <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
    </td>
    <td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:45.58%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andrew I. Koven</font></p>
    </td>
   </tr>
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
    </td>
    <td width="45%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:45.58%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew I. Koven</font></p>
    </td>
   </tr>
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
    </td>
    <td width="45%" valign="top" style="padding:0in .7pt 0in .7pt;width:45.58%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive Vice President, General Counsel and Corporate
    </font></p>
    </td>
   </tr>
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="6%" valign="top" style="padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="45%" valign="top" style="padding:0in .7pt 0in .7pt;width:45.58%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Secretary</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  <!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\tbamidi\08-13159-2\task2907807\13159-2-ba.htm',USER='tbamidi',CD='Apr 30 19:30 2008' -->
  
  
  </body>
  
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "a08-13159_28k.htm", "description": "8-K", "secsgml_size_bytes": 32110}]
metadata_filer: {"company-data": {"conformed-name": "SEPRACOR INC /DE/", "cik": "0000877357", "assigned-sic": "2834", "irs-number": "222536587", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19410", "film-number": "08791958"}, "business-address": {"street1": "84 WATERFORD DRIVE", "city": "MARLBOROUGH", "state": "MA", "zip": "01757", "phone": "5084816700"}, "mail-address": {"street1": "84 WATERFORD DRIVE", "city": "MARLBOROUGH", "state": "MA", "zip": "01752"}}
text: UNITED
  STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT
  REPORT
  Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
  1934
  Date of Report
  (Date of earliest event reported):
  April 30, 2008
  Sepracor
  Inc.
  (Exact Name of
  Registrant as Specified in its Charter)
  Delaware
  0-19410
  22-2536587
  (State or Other
    Juris-
  diction of Incorporation
  (Commission
  File Number)
  (IRS Employer
  Identification No.)
  84
    Waterford Drive
  Marlborough, MA
  01752
  (Address of Principal
    Executive Offices)
  (Zip Code)
  Registrant's
  telephone number, including area code:
  (508)
  481-6700
  (Former Name or
  Former Address, if Changed Since Last Report)
  Check the appropriate box below if the Form 8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions (see General Instruction A.2. below):
  o
  Written communications pursuant to Rule 425
  under the Securities Act (17 CFR 230.425)
  o
  Soliciting material pursuant to Rule 14a-12
  under the Exchange Act (17 CFR 240.14a-12)
  o
  Pre-commencement communications pursuant
  to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  o
  Pre-commencement communications pursuant
  to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  Item 1.01  Entry into a Material Definitive Agreement.
  Levalbuterol/ipratropium License
  and Development Agreement
  On April 30, 2008,
  Sepracor Inc. (the "Company") entered into a License and Development Agreement
  (the "Levalbuterol/ipratropium Agreement") with Arrow International Limited
  ("Arrow") for the development, commercialization, marketing, sale and
  distribution of Arrow's levalbuterol/ipratropium combination inhalation
  solution product in current and all future formulations and delivery modes (the
  "Levalbuterol/ipratropium Product") throughout the world.
  Under the
  Levalbuterol/ipratropium Agreement, Arrow will receive an upfront payment of
  $500,000 upon execution of the Levalbuterol/ipratropium Agreement.  Arrow shall also be entitled to receive a
  $25,000,000 payment on December 15, 2009, a $25,000,000 payment on December 15,
  2010 as further consideration for the transfer of know how and the grants of
  rights and licenses to the Arrow technology, provided Arrow is not in material
  breach of certain of its obligations under the Levalbuterol/ipratropium
  Agreement, and a milestone payment of $20,000,000 upon receipt of marketing
  clearance for the Levalbuterol/ipratropium Product in the United States. The
  Company will also pay single-digit royalties that escalate based on product
  sales, subject to Arrow electing to receive a discounted amount in lieu of
  ongoing royalty payments.
  The Company will have
  responsibility for all aspects of the development and commercialization of the
  Levalbuterol/ipratropium Product.  The
  Company will fully fund all product development activities and manage the
  development program, including all interactions with the U.S. Food and Drug
  Administration and other regulatory bodies. 
  Arrow will assist the Company with the development.
  Arrow has the right to
  manufacture and supply the Company with its requirements of the
  Levalbuterol/ipratropium Product.  If
  Arrow elects not to manufacture and supply the Levalbuterol/ipratropium Product
  to the Company, then the Company will have the right to manufacture or arrange
  for the manufacture of the Levalbuterol/ipratropium Product.
  The
  Levalbuterol/ipratropium Agreement will remain in effect until the later of, on
  a product by product basis, the last to expire of any patent with a claim
  covering the Levalbuterol/ipratropium Product, or 12 years after the first
  commercial sale of the Levalbuterol/ipratropium Product on a country by country
  basis.  The agreement also contains
  customary early termination and non-compete provisions.
  Ciclesonide License and
  Development Agreement
  On April 30,
  2008, the Company entered into a License and Development Agreement (the
  "Ciclesonide Agreement") with Arrow for the development, commercialization,
  marketing, sale and distribution of an inhalation pharmaceutical product
  containing ciclesonide as its only active ingredient and an inhalation
  pharmaceutical product containing both ciclesonide and arformoterol as its
  active ingredients throughout the world (collectively, the "Ciclesonide Products")
  as well as Arrow's "U-Bend" packaging technology which allows increased
  accuracy in dosing through a novel U-Bend ampule design.
  Under the
  Ciclesonide Agreement, Arrow will receive an upfront payment of $500,000 upon
  execution of the Ciclesonide Agreement. 
  Arrow shall also be entitled to receive a $10,000,000 payment on December 15,
  2009, a $10,000,000 payment on December 15, 2010, as further consideration
  for the transfer of know how and the grants of rights and licenses to the Arrow
  technology, provided Arrow is not in material breach of certain of its
  obligations under the Levalbuterol/ipratropium Agreement, and milestone
  payments of up to an aggregate of $27,500,000 upon the achievement of certain
  regulatory milestones relating to both the Ciclesonside Products.  The Company will also pay single-digit
  royalties on sales of the Ciclesonide Products, subject to Arrow electing to
  receive discounted amounts in lieu of ongoing royalty payments.
  2
  The Company and
  Arrow will be jointly responsible for the development of the Ciclesonide
  Products.  The Company will fully fund
  all product development activities and manage the development program,
  including all interactions with the U.S. Food and Drug Administration and other
  regulatory bodies.  The Company is
  exclusively responsible for all commercial activities associated with the
  Ciclesonide Products.
  The Ciclesonide
  Agreement will remain in effect until the later of, on a product by product
  basis, the last to expire of any patent with a claim covering the Ciclesonide
  Products, or 12 years after the first commercial sale of one of the Ciclesonide
  Products on a country by country basis. 
  The Ciclesonide Agreement also contains customary early termination and
  non-compete provisions.
  Forward-Looking Statements
  This Report on Form 8-K
  contains forward-looking statements that involve risks and uncertainties,
  including statements with respect to the development, commercialization,
  marketing, sale, and distribution of products containing
  levalbuterol/ipratropium, ciclesonide, and ciclesonide/arformoterol, the supply
  of finished product by Arrow and future payments by the Company to Arrow.  Among the factors that could cause actual
  results to differ materially from those indicated by such forward-looking
  statements are: the clinical benefits, efficacy and safety of products covered
  by the agreements referenced in this report; the timing and success of the
  development of products covered by the agreements referenced in this report;
  unexpected delays in commercial introduction and the commercial success of
  products covered by the agreements referenced in this report; Arrow's ability
  to supply or obtain from third parties the Company's requirements for products
  or components covered by the Agreement; the success of the Company's
  relationship with Arrow; the scope of Arrow's and/or the Company's patents and
  the patents of others; the ability of the Company and Arrow to attract and
  retain qualified personnel; and certain other factors that may affect future
  operating results that are detailed in the Company's annual report on Form 10-K
  for the year ended December 31, 2007 filed with the Securities and
  Exchange Commission.
  In addition, the
  statements in this Report on Form 8-K represent the Company's expectations
  and beliefs as of the date of this Report. Subsequent events and developments
  may cause these expectations and beliefs to change. However, while the Company
  may elect to update these forward-looking statements at some point in the
  future, unless required by applicable law, it specifically disclaims any
  obligation to do so.  These
  forward-looking statements should not be relied upon as representing the
  Company's expectations or beliefs as of any date subsequent to the date of this
  Report on Form 8-K.
  3
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  Sepracor Inc.
  Date: May 1, 2008
  By:
  /s/ Andrew I. Koven
  Name:
  Andrew I. Koven
  Title:
  Executive Vice President, General Counsel and Corporate
  Secretary
  4